423 related articles for article (PubMed ID: 33939171)
1. Elicitation of Rheumatologist Preferences for the Treatment of Patients with Rheumatoid Arthritis After the Failure of a First Conventional Synthetic Disease-Modifying Anti-Rheumatic Agent.
Senbel E; Durand F; Roux B; Badaoui FZ; Fautrel B
Rheumatol Ther; 2021 Jun; 8(2):921-935. PubMed ID: 33939171
[TBL] [Abstract][Full Text] [Related]
2. Factors influencing the choice of first- and second-line biologic therapy for the treatment of rheumatoid arthritis: real-life data from the Italian LORHEN Registry.
Monti S; Klersy C; Gorla R; Sarzi-Puttini P; Atzeni F; Pellerito R; Fusaro E; Paolazzi G; Rocchetta PA; Favalli EG; Marchesoni A; Caporali R
Clin Rheumatol; 2017 Apr; 36(4):753-761. PubMed ID: 28058538
[TBL] [Abstract][Full Text] [Related]
3. Choice of second-line disease-modifying antirheumatic drugs after failure of methotrexate therapy for rheumatoid arthritis: a decision tree for clinical practice based on rheumatologists' preferences.
Fautrel B; Guillemin F; Meyer O; de Bandt M; Berthelot JM; Flipo RM; Lioté F; Maillefert JF; Wendling D; Saraux A; Combe B; Le Loët X; ; ;
Arthritis Rheum; 2009 Apr; 61(4):425-34. PubMed ID: 19333993
[TBL] [Abstract][Full Text] [Related]
4. Factors influencing prescribing the first add-on disease-modifying antirheumatic drugs in patients initiating methotrexate for rheumatoid arthritis.
Huang Y; Chatterjee S; Agarwal SK; Chen H; Johnson ML; Aparasu RR
Explor Res Clin Soc Pharm; 2023 Sep; 11():100296. PubMed ID: 37521021
[TBL] [Abstract][Full Text] [Related]
5. 2017 recommendations of the Brazilian Society of Rheumatology for the pharmacological treatment of rheumatoid arthritis.
Mota LMHD; Kakehasi AM; Gomides APM; Duarte ALBP; Cruz BA; Brenol CV; de Albuquerque CP; Castelar Pinheiro GDR; Laurindo IMM; Pereira IA; Bertolo MB; Ubirajara Silva de Souza MPG; de Freitas MVC; Louzada-Júnior P; Xavier RM; Giorgi RDN
Adv Rheumatol; 2018 May; 58(1):2. PubMed ID: 30657071
[TBL] [Abstract][Full Text] [Related]
6. Retention rate of a second line with a biologic DMARD after failure of a first-line therapy with abatacept, tocilizumab, or rituximab: results from the Italian GISEA registry.
Sebastiani M; Venerito V; Bugatti S; Bazzani C; Biggioggero M; Petricca L; Foti R; Bortoluzzi A; Balduzzi S; Visalli E; Frediani B; Manfredi A; Gremese E; Favalli E; Iannone F; Ferraccioli G; Lapadula G;
Clin Rheumatol; 2021 Oct; 40(10):4039-4047. PubMed ID: 33881676
[TBL] [Abstract][Full Text] [Related]
7. Singapore Chapter of Rheumatologists updated consensus statement on the eligibility for government subsidization of biologic and targeted-synthetic therapy for the treatment of rheumatoid arthritis.
Leong JWY; Cheung PP; Dissanayake S; Fong WWS; Leong KH; Leung YY; Lim AYN; Lui NL; Manghani M; Santosa A; Sriranganathan MK; Suresh E; Tan TC; Teng GG; Lahiri M
Int J Rheum Dis; 2020 Feb; 23(2):140-152. PubMed ID: 31859424
[TBL] [Abstract][Full Text] [Related]
8. Tofacitinib for Treating Rheumatoid Arthritis After the Failure of Disease-Modifying Anti-rheumatic Drugs: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
Uttley L; Bermejo I; Ren S; Martyn-St James M; Wong R; Scott DL; Young A; Stevenson M
Pharmacoeconomics; 2018 Sep; 36(9):1063-1072. PubMed ID: 29546668
[TBL] [Abstract][Full Text] [Related]
9. The effect of methotrexate versus other disease-modifying anti-rheumatic drugs on serum drug levels and clinical response in patients with rheumatoid arthritis treated with tumor necrosis factor inhibitors.
Martínez-Feito A; Plasencia-Rodríguez C; Navarro-Compán V; Hernández-Breijo B; González MÁ; Monjo I; Nuño L; Nozal P; Pascual-Salcedo D; Balsa A
Clin Rheumatol; 2019 Mar; 38(3):949-954. PubMed ID: 30402698
[TBL] [Abstract][Full Text] [Related]
10. Treatment patterns in rheumatoid arthritis after discontinuation of methotrexate: data from the Ontario Best Practices Research Initiative (OBRI).
Pope JE; Rampakakis E; Movahedi M; Cesta A; Li X; Couto S; Sampalis JS; Bombardier C;
Clin Exp Rheumatol; 2018; 36(2):215-222. PubMed ID: 29148403
[TBL] [Abstract][Full Text] [Related]
11. Alternative tumour necrosis factor inhibitors (TNFi) or abatacept or rituximab following failure of initial TNFi in rheumatoid arthritis: the SWITCH RCT.
Brown S; Everett CC; Naraghi K; Davies C; Dawkins B; Hulme C; McCabe C; Pavitt S; Emery P; Sharples L; Buch MH
Health Technol Assess; 2018 Jun; 22(34):1-280. PubMed ID: 29900829
[TBL] [Abstract][Full Text] [Related]
12. Malignant Neoplasms in Patients With Rheumatoid Arthritis Treated With Tumor Necrosis Factor Inhibitors, Tocilizumab, Abatacept, or Rituximab in Clinical Practice: A Nationwide Cohort Study From Sweden.
Wadström H; Frisell T; Askling J;
JAMA Intern Med; 2017 Nov; 177(11):1605-1612. PubMed ID: 28975211
[TBL] [Abstract][Full Text] [Related]
13. Comparative effectiveness of tocilizumab versus TNF inhibitors as monotherapy or in combination with conventional synthetic disease-modifying antirheumatic drugs in patients with rheumatoid arthritis after the use of at least one biologic disease-modifying antirheumatic drug: analyses from the pan-European TOCERRA register collaboration.
Lauper K; Nordström DC; Pavelka K; Hernández MV; Kvien TK; Kristianslund EK; Santos MJ; Rotar Ž; Iannone F; Codreanu C; Lukina G; Gale SL; Sarsour K; Luder Y; Courvoisier DS; Gabay C
Ann Rheum Dis; 2018 Sep; 77(9):1276-1282. PubMed ID: 29730637
[TBL] [Abstract][Full Text] [Related]
14. Combination therapy with biologic agents in rheumatic diseases: current and future prospects.
Inui K; Koike T
Ther Adv Musculoskelet Dis; 2016 Oct; 8(5):192-202. PubMed ID: 27721905
[TBL] [Abstract][Full Text] [Related]
15. Use and effectiveness of tocilizumab among patients with rheumatoid arthritis: an observational study from the British Society for Rheumatology Biologics Register for rheumatoid arthritis.
Kihara M; Davies R; Kearsley-Fleet L; Watson KD; Lunt M; Symmons DP; Hyrich KL;
Clin Rheumatol; 2017 Feb; 36(2):241-250. PubMed ID: 27913894
[TBL] [Abstract][Full Text] [Related]
16. Sarilumab for Previously-Treated Moderate or Severe Rheumatoid Arthritis: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
Bermejo I; Ren S; Simpson E; Clowes M; Scott DL; Young A; Stevenson M
Pharmacoeconomics; 2018 Dec; 36(12):1427-1437. PubMed ID: 29882210
[TBL] [Abstract][Full Text] [Related]
17. Cancer risk with tocilizumab/sarilumab, abatacept, and rituximab treatment in patients with rheumatoid arthritis: a Danish cohort study.
Westermann R; Cordtz RL; Duch K; Mellemkjaer L; Hetland ML; Magnussen B; Dreyer L
Rheumatology (Oxford); 2024 Mar; ():. PubMed ID: 38452297
[TBL] [Abstract][Full Text] [Related]
18. Treating to target in established rheumatoid arthritis: Challenges and opportunities in an era of novel targeted therapies and biosimilars.
Woodworth TG; den Broeder AA
Best Pract Res Clin Rheumatol; 2015; 29(4-5):543-9. PubMed ID: 26697765
[TBL] [Abstract][Full Text] [Related]
19. Risk factors associated with initiation of a biologic disease modifying anti-rheumatic drug in patients with rheumatoid arthritis: A nested case-control study on 34,925 patients.
Park EH; Shin A; Ha YJ; Lee YJ; Lee EB; Song YW; Kang EH
Joint Bone Spine; 2021 Jan; 88(1):105057. PubMed ID: 32711117
[TBL] [Abstract][Full Text] [Related]
20. Factors influencing clinician prescribing of disease-modifying anti-rheumatic drugs for inflammatory arthritis: A systematic review and thematic synthesis of qualitative studies.
Lalor AF; Brooker JE; Rozbroj T; Whittle SL; Hill CL; Rowett D; Buchbinder R; O'Connor DA
Semin Arthritis Rheum; 2022 Aug; 55():151988. PubMed ID: 35286905
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
